Belmont Diagnostics
EGUILLES / 190 rue Topaze
Creation:|
Our Vision is to “make health testing a commodity” so that the greatest number of people can follow their health and intervene when it is the most effective. Our device allows to isolate plasma, mix with a reagent and deposit into a lateral flow immunoassay (LFI) or quick test. We can adapt our device to any commercially available quick test and biomarker that require plasma as a sample matrix. This is particularly important and applicable for biomarkers of low abondance. We have identified several candidate biomarkers that could benefit from our technology such as hs-CRP for cardiovascular disease, spike protein for long covid and suPAR for chronic inflammation amongst others. |
|||||||||
| Business axis : |
Diagnostic E-health
|
||||||||
| Category : | TPE | ||||||||
| Legal form : | SAS | ||||||||
| Number of employees : | 3 | ||||||||
| Website : | https://belmontdiagnostics.com/ | ||||||||
| Turnover : |
0.00 K€ |
||||||||
| Reference technologies : | |||||||||